Q101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology)

N/A

Report date: 2025/03/20 15:10:19

Base Information

Drug NameQ101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology)
Drug Alias Name聚乙二醇重组人干扰素α2aQ101-PEG-IFN-alfa-2a (CSPC Zhongqi Pharmaceutical Technology)Q101-聚乙二醇重组人干扰素α2a
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha 2 ligandInterferon alpha/beta receptor inhibitors
TargetsInterferon alpha-2Interferon alpha/beta receptor
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A